Telix Pharmaceuticals Ltd 3 Filing
Ticker: TLX · Form: 3 · Filed: Apr 1, 2026 · CIK: 0002007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLX) |
| Form Type | 3 |
| Filed Date | Apr 1, 2026 |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 3 filing submitted by Telix Pharmaceuticals Ltd (ticker: TLX) to the SEC on Apr 1, 2026.
How long is this filing?
Telix Pharmaceuticals Ltd's 3 filing is 1 pages with approximately 445 words. Estimated reading time is 2 minutes.
Where can I view the full 3 filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 8.9 · Accepted 2026-04-01 07:24:42
Filing Documents
- wk-form3_1775042676.html (3)
- wk-form3_1775042676.xml (3) — 3KB
- poa-marknelson.htm (EX-24) — 5KB
- poa-marknelson001.jpg (GRAPHIC) — 233KB
- poa-marknelson002.jpg (GRAPHIC) — 94KB
- 0001628280-26-022570.txt ( ) — 460KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Nelson Mark Alexander (Last) (First) (Middle) C/O TELIX PHARMACEUTICALS LTD 55 FLEMINGTON RD (Street) NORTH MELBOURNE 3051 (City) (State) (Zip) AUSTRALIA (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol Telix Pharmaceuticals Ltd [ TLX ] 3a. Foreign Trading Symbol [ TLX ] 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 3,628,750 I MAN Holdings Pty Ltd (1) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. MAN Holdings Pty Ltd, as Trustee for the Nelson Hybrid Trust, of which Mr. Nelson is a director and shareholder. Remarks: Ex. 24 - Power of Attorney /s/ Oliver Newman, on behalf of Mr. Mark Nelson 04/01/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)